Iveric Bio Shares Rise 16% After FDA Accepts New Drug App for Avacincaptad Pegol
17 Febrero 2023 - 9:54AM
Noticias Dow Jones
By Chris Wack
Iveric bio Inc. shares were up 16% to $23.20 after the company
said the U.S. Food and Drug Administration completed its filing
review and accepted its new drug application for avacincaptad
pegol.
Avacincaptad pegol is a novel investigational complement C5
inhibitor for the treatment of geographic atrophy secondary to
age-related macular degeneration, according to Iveric.
The Parsippany, N.J.-based biopharmaceutical company said the
new drug application has been granted a priority review with a
Prescription Drug User Fee Act goal date of Aug. 19, 2023. The
company also said that, at this time, the FDA hasn't identified any
potential review issues and planned to hold an advisory committee
meeting for the drug.
The new drug application was submitted based on 12-month
pre-specified primary efficacy and safety results.
Iveric bio shares hit their 52-week high of $24.56 on Feb. 2,
and are up 59% over the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 17, 2023 10:39 ET (15:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
IVERIC bio (NASDAQ:ISEE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
IVERIC bio (NASDAQ:ISEE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
